Oct 31, 2020

Phreesia Q3 2021 Earnings Report

Announced fiscal third quarter 2021 results with revenue increasing by 17% year-over-year.

Key Takeaways

Phreesia reported revenue of $38.5 million for the fiscal third quarter ended October 31, 2020, representing a 17% increase compared to the same period in the prior year. The average number of provider clients increased by 10% to 1,737, and the average revenue per provider client increased by 5% to $17,490. Adjusted EBITDA was positive $1.2 million. Cash and cash equivalents totaled $254.1 million.

Revenue was $38.5 million, up 17% year-over-year.

Average provider clients were 1,737, a 10% increase year-over-year.

Average revenue per provider client was $17,490, up 5% year-over-year.

Adjusted EBITDA was positive $1.2 million.

Total Revenue
$38.5M
Previous year: $32.8M
+17.1%
EPS
-$0.09
Previous year: -$0.07
+28.6%
Revenue per Provider Client
$17.5K
Previous year: $16.6K
+5.1%
Patient Payment Volume
$524M
Previous year: $463M
+13.2%
Gross Profit
$24.5M
Cash and Equivalents
$254M
Free Cash Flow
-$2.45M
Total Assets
$338M

Phreesia

Phreesia

Phreesia Revenue by Segment

Forward Guidance

For the full fiscal year 2021, ending January 31, 2021, the Company expects to report revenue of $146 to $147 million. For the full fiscal year 2022, ending January 31, 2022, the Company expects revenue to grow between 20 and 25 percent over fiscal year 2021.

Positive Outlook

  • Revenue of $146 to $147 million expected for fiscal year 2021.
  • Revenue growth of 20 to 25 percent expected for fiscal year 2022 over fiscal year 2021.

Challenges Ahead

  • Uncertainty regarding the impact of the COVID-19 pandemic on business operations, financial performance, and results of operations.
  • Potential impact from surges of COVID-19 cases and additional restrictions on patient visits.
  • Disruptions to provider operations may impact subscription and related services revenue.
  • Decline in non-essential and elective patient visits may impact revenue from payment processing tools.
  • Decline in patient visits may impact revenue earned through patient engagement in life sciences.

Revenue & Expenses

Visualization of income flow from segment revenue to net income